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Abstract
Ataxia Telangiectasia (A-T) is an inherited immunodeficiency disorder wherein mutation of the ATM kinase is responsible for
the A-T pathogenesis. Although the precise role of ATM in A-T pathogenesis is still unclear, its function in responding to
DNA damage has been well established. Here we demonstrate that in addition to its role in DNA repair, ATM also regulates
proteasome-mediated protein turnover through suppression of the ISG15 pathway. This conclusion is based on three major
pieces of evidence: First, we demonstrate that proteasome-mediated protein degradation is impaired in A-T cells. Second,
we show that the reduced protein turnover is causally linked to the elevated expression of the ubiquitin-like protein ISG15
in A-T cells. Third, we show that expression of the ISG15 is elevated in A-T cells derived from various A-T patients, as well as
in brain tissues derived from the ATM knockout mice and A-T patients, suggesting that ATM negatively regulates the ISG15
pathway. Our current findings suggest for the first time that proteasome-mediated protein degradation is impaired in A-T
cells due to elevated expression of the ISG15 conjugation pathway, which could contribute to progressive
neurodegeneration in A-T patients.
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Introduction
Ataxia Telangiectasia (A-T) (Boder-Sedgwick/Louis-Bar syn-
drome) is an inherited immunodeficiency disorder with a
prevalence rate of 1 in 30,000–100,000 births [1–3]. A-T patients
are characterized by pronounced facial spider veins (telangiectsia),
recurrent sinopulmonary infections, and an irregular gait (ataxia)
that results from progressive neuronal dysfunction [4]. These
clinical presentations, which are secondary to sensitivity to ionizing
radiation and a marked predisposition to cancer, were explicated
in 1995 by Savitsky et al. as an autosomal recessive mutation in the
Ataxia Telangiectasia Mutated (ATM) gene. ATM is a 370 kDa
nuclear Ser/Thr kinase that contributes to the regulation of p53,
BRCA1, and Chk2 signaling pathways, amongst others. As such, it
is required for progression through mitotic checkpoints, double
strand DNA repair, telomere repair, apoptosis and meiosis [2].
The central role of ATM in cell regulation suggests that a loss of
function mutations in the ATM gene should result in broadly
pleiotropic effects.
ISG15 (Interferon-Stimulated Gene 15) is a member of the
UBL (ubiquitin-like protein) superfamily of proteins that includes
Nedd8 and SUMO1, amongst others [5,6]. ISG15 is conjugated to
its target proteins (ISGylation) in an enzymatic cascade that
involves specific E1, E2 and E3 enzymes [7,8]. Its conjugating
enzymes are also induced by type I interferons [9–13]. UBE1L
and UbcH8 have been identified as the specific E1 and E2
enzymes for ISG15 conjugation respectively [9,13,14]. Although
several E3s have been identified as possible ISG15 E3 ligases, the
major E3 for ISG15 appears to be HERC5 [10,11]. However, the
partial loss of ISG15 conjugates in HERC5-ablated cells suggests
that other ISG15 E3 ligases may contribute to ISG15 conjugation
in vivo. ISG15 conjugation is reversible. UBP43 has been identified
as an enzyme responsible for the deconjugation of ISG15 from
target substrates [15].
ISG15 exists in both free [16] and target-conjugated forms [7].
Initial studies suggested that free ISG15 serves as an immuno-
modulatory cytokine secreted by a non-canonical mechanism in
response to Type I interferon induction [17]. As an extracellular
cytokine, purified ISG15 can activate natural killer and cytotoxic
T-cells [16], stimulate IFN-c production [16], induce dendritic cell
maturation [18] and neutrophil recruitment [19], suggesting the
likely role of ISG15 in immune surveillance. Several studies now
demonstrate that intracellular free ISG15 and conjugated ISG15
play an important role in innate immunity against viral infection
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immunological effects of interferon [21].
Early studies to determine the function of ISG15 suggested that
ISGylation may facilitate proteasomal degradation of selected
proteins. One study in support of this hypothesis demonstrated
that overexpression of UBE1L stimulates PML/RARa degrada-
tion in NB4 APL cells treated with retinoic acid [22]. However,
more recent work has demonstrated that direct ISG15 conjugation
to Serpin 2a, JAK, or STAT1 does not increase their respective
rates of degradation [23,24], suggesting that the role of ISGylation
in PML-RARa degradation may be indirect. On the other hand, it
is becoming increasingly clear that ISG15 exerts its biological
effect by interfering with the ubiquitin pathway. ISG15 inhibits the
ubiquitylation of Gag and Tsg101 which prevents their interaction
and blocks retroviral replication and release [25]. In addition,
ISG15 inhibits Nedd4 ubiquitin ligase and, consequently, the
ubiquitylation of VP40 viral particles essential for budding of
Ebola viruses [26,27]. Furthermore, ISG15 inhibits ubiquitin-
mediated degradation of IRF3, a transcription factor involved in
the interferon response, and enhances innate antiviral immunity
[28]. A possible mechanism for broader inhibition of ubiquitin-
dependent targeting pathways has been suggested by UbcH8-
ISG15 acting as an alternate substitute for ligases specific for the
closely related ubiquitin-specific UbcH7 and the UbcH5 clade
[29]. Indeed, several groups have now demonstrated that ISG15
inhibit polyubiquitylation by modulating the activities of selected
ubiquitin E2 and E3 ligases [26,27,30–32]. In normal cells, the
ISG15 pathway is not constitutively elevated. However, when
aberrantly overexpressed, ISG15 could either compete with
ubiquitin to bind to the ubiquitin E2/E3 ligases as proposed by
Haas [29], or it could conjugate to and inhibit the activity of
ubiquitin E2/E3 ligases as demonstrated with Nedd4 [26,27],
UbcH6 [30], and UbcH13 [31,32]. Inhibition of the ubiquitin
ligation is, therefore, expected to decrease protein polyubiquityla-
tion and proteasome-mediated degradation of cellular proteins.
Indeed, ISG15 inhibits bulk polyubiquitylation and the subsequent
26S proteasome-mediated degradation of target proteins in breast
cancer cells [33]. In addition, elevated expression of ISG15
suppresses camptothecin-induced proteasome-mediated degrada-
tion of topoisomerase I in breast cancer cells [34], further
supporting the antagonistic role of ISG15 in ubiquitin-mediated
degradation of many endogenous cellular proteins.
ISG15 is elevated and conjugated to cellular proteins in A-T
cells [35]. However, the functional significance of ATM in
regulating (suppressing) ISG15 expression and ISGylation is
unclear. Because ISG15 interferes with ubiquitylation in tumor
cells [33], it prompted us to test the possibility that ATM may
regulate the ubiquitin/26S proteasome pathway through suppres-
sion of ISG15. Our results show that cells with defective ATM
exhibit reduced protein polyubiquitylation and turnover. The
reduced protein turnover in A-T cells is associated with elevated
expression of ISG15. In addition, specific knockdown of either
ISG15 or UbcH8, ISG15-specific conjugating enzyme (E2)
restores protein polyubiquitylation and turnover in A-T cells.
Our results support a model in which ATM negatively regulates
proteasome-mediated protein degradation through the ISG15
conjugation pathway. In support of such a model, we have also
demonstrated that the ISG15 pathway is elevated not only in
various A-T cell lines derived from A-T patients, but also in brain
tissues of ATM knockout mice and A-T patients. As defective
protein turnover in neurons has been a hallmark of many
neurological diseases [36–41], our results point to the possibility
for the first time that ISG15-mediated impairment of protein
degradation in A-T neurons could contribute to the progressive
neurodegeneration in A-T patients. The presence of Lys63-linked
polyubiquitin and ISG15 inclusions/aggregates in the mid-brain
sections obtained from A-T patients further strengthens this
possibility.
Results
Protein polyubiquitylation and degradation is reduced in
cells deficient in ATM
Accumulation of non-degraded proteins due to the lesions in the
ubiquitin pathway has been speculated to contribute to the
pathology of many neurodegenerative diseases [36–41]. Ataxia
Telangiectasia (A-T) patients also show progressive neurodegener-
ation [42]. However, the reason for the progressive neurodegen-
eration in A-T is, so far, not known. To test whether like other
neurodegenerating diseases, the defective ubiquitin-mediated
degradation of cellular proteins contributes to neurodegeneration
in A-T, we monitored the rate of degradation of overall cellular
polyubiquitylated proteins in FT169A (A-T) (ATM null) and
FT169A (ATM+) (ATM reconstituted FT169A) isogenic cells [43]
using the protein synthesis inhibitor cycloheximide (CHX) [44]. As
shown in Fig. 1A, the level of polyubiquitylated proteins (see
protein species marked by * (smear of high molecular weight
(HMW) ubiquitin-conjugated (polyubiquitylated) proteins and **
(high molecular weight polyubiquitylated proteins migrating as a
compressed band) remained relatively unchanged in FT169A (A-
T) cells up to six hours in the presence of CHX (compare lanes 1
and 4 and lower panel for quantification), suggesting minimal
turnover of polyubiquitylated proteins in A-T cells. By contrast,
the level of polyubiquitylated proteins (marked by* and **) was
reduced by more than 30% within 6 hours in FT169A (ATM+)
cells under the same conditions (Fig. 1A, compare lanes 5 and 8
and lower panel for the quantification). We also observed
increased steady state level of the high molecular weight (HMW)
ubiquitin-conjugated (polyubiquitylated) proteins (marked by *) in
FT169A (ATM+) as compared to FT169A (A-T) cells (Fig. 1A,
compare lanes 1 and 5) in Western analysis using anti-ubiquitin
antibodies. The same membrane shown in Fig. 1A was stripped
and re-probed with anti-ISG15 antibodies. The band intensities of
the ISG15 protein remained same in FT169A (A-T) (lanes 1–4)
and (ATM+) (lanes 5–8) cells (note that ISG15 protein levels are
low in ATM+ as compared to A-T cells (see discussion below))
treated with CHX. These results revealed that targeted degrada-
tion of the polyubiquitylated proteins is specifically altered in A-T
cells.
The ubiquitin antibody used in the above experiment is known
to cross-react with free, but not conjugated, ISG15/UCRP [8]. In
order to rule out the possibility that the polyubiquitylated proteins
(see species marked by *) identified in Fig. 1A are not due to a
cross-reaction with the ISG15 protein and/or other UBL-protein
conjugates, HA-tagged ubiquitin cDNA was transfected into
FT169A (A-T) and FT169A (ATM+) cells. The amount of
polyubiquitylated proteins, and the rate of turnover of these
polyubiquitylated proteins (see the HMW protein species marked
by *) were then determined under the same conditions as in
Fig. 1A, except that anti-HA, rather than an anti-ubiquitin
antibody was used in immunoblotting. As shown in Fig. 1B, the
amount of HMW HA-ubiquitin-conjugated (polyubiquitylated)
proteins (marked by *) was elevated in FT169A (ATM+)a s
compared to FT169A (A-T) cells (Fig. 2B, compare lanes 1 and 4),
consistent with results obtained by measuring the endogenous
polyubiquitylated proteins in FT169A (A-T) and FT169A (ATM+)
cells shown in Fig. 1A. The difference in the migration of
polyubiquitylated proteins seen in Fig. 1A (migrating as a smear *
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band **) is due to the different gel systems used in these
experiments (5 and 15% discontinuous gel vs. 15% gel
respectively). The turnover of HA-ubiquitin-conjugated proteins
(species marked by **), measured in the presence of CHX (10 mg/
ml) for 6 hours, was negligible in FT169A (A-T) cells (Fig. 1B,
compare lanes 1 and 2 and lower panels for quantification). By
contrast, about two-thirds of HA-ubiquitin-conjugated proteins
were degraded in FT169A (ATM+) cells within 6 hours under the
same conditions (Fig. 1B, compare lanes 4 and 5 and lower panels
for quantification). The bar graph in the supplementary Fig. S1
shows average (+/- SEM) rate of degradation of the HA-
Figure 1. Protein turnover is reduced in A-T cells. A. FT169A (A-T) (lanes 1–4) and FT169A (ATM+) (lanes 5-8) cells were treated with the protein
synthesis inhibitor CHX (10 mg/ml) for 0, 1, 3, and 6 hours. Cell lysates were analyzed using discontinuous (5%/15%) SDS-PAGE followed by
immunoblotting with anti-ubiquitin antibody. The symbols * and ** mark the position of high-molecular-weight (HMW) polyubiquitylated proteins.
Quantitation of the high-molecular-weight (HMW) polyubiquitylated proteins (shown as **) is shown in the bar graph. B. FT169A (A-T) (lanes 1 and 2)
and FT169A (ATM+) (lanes 3 and 4) cells were transfected with HA-ubiquitin as described in Methods. Forty-eight hours post-transfection, cells were
treated with the protein synthesis inhibitor CHX (marked on top of each lane) for 6 hours. Cell lysates were analyzed using 15% SDS-PAGE followed
by immunoblotting with anti-HA antibody. The symbol ** marks the position of polyubiquitylated proteins (compressed due to the gel
electrophoresis conditions). Quantitation of the high-molecular-weight (HMW) polyubiquitylated proteins (shown as **) is shown in the bar graph. C.
FT169A (A-T) and FT169A (ATM+) cells were transfected with HA-Lys48-only (left panel) and Lys63-only (right panel) ubiquitin constructs. Thirty hours
post-transfection, cells were treated with the protein synthesis inhibitor CHX (marked on the top of each lane) for 3 hours and then analyzed by
immunoblotting with anti-HA antibodies as described above. All the experiments were repeated at least three times and the representative
experiments are shown.
doi:10.1371/journal.pone.0016422.g001
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from three independent experiments. The same membrane shown
in Fig. 1B was stripped and re-probed with anti-ISG15 antibodies.
The band intensities of the ISG15 protein remained unaltered in
FT169A (A-T) (lanes 1–2) and (ATM+) (lanes 3–4) cells treated
with CHX. These results revealed that targeted degradation of the
HA-polyubiquitylated proteins is specifically altered in A-T cells.
These results obtained with anti-HA-ubiquitin antibody are
consistent with results obtained from the use of an anti-ubiquitin
antibody (see Western blots (upper panels) and bar graphs showing
quantitation of a 200 kDa band (**) (lower panels) comprised of
polyubiquitylated proteins in Fig. 1A and B, and supplementary
Fig. S1), suggesting that ATM regulates both the amount and the
rate of degradation of polyubiquitylated proteins.
The ubiquitin sequence contains seven lysine residues (at
positions 6, 11, 27, 29, 33, 48, and 63) and polyubiquitin chain
assembly can occur at any of these lysine residues [45]. Lys48-
linked polyubiquitylated proteins are targeted for destruction via
Figure 2. The 26S proteasome-mediated turnover of proteins is impaired in A-T cells. A and B. FT169A (A-T) and FT169A (ATM+) cells
transfected with fluorescent reporter proteasome substrates (the ubiquitin fusion degradation substrate, Ub
G76V-YFP (panel A), and the N-end rule
substrate, ubiquitin-arginine-YFP (Ub-R-YFP) (panel B) for 12 hours. Proteasome inhibitor MG132 (0.5 mM) was then added to the transfection
medium and cells were allowed to grow for an additional 12 hours. After washing (to remove MG132), cells were treated with protein synthesis
inhibitor CHX (10 mg/ml) for 3 hours. The fluorescent reporter levels were detected with GFP antibodies. C. FT169A (A-T) and FT169A (ATM+) cells
were treated with the protein synthesis inhibitor CHX (10 mg/ml) in the presence (lanes 3 and 6) or absence (lanes 2 and 5) of the proteasome
inhibitor MG132 (10 mM) for 6 hours. Cell lysates were analyzed by immunoblotting using an anti-p53 antibody (upper panel). The intensity of the
p53 bands was measured using a Kodak Image station 2000R (BioRad). Results are shown in a bar graph (right panel). The filter used for
immunoblotting was stained with Ponceau S to assure equal protein loading (lower panel). D. FT169A (A-T) (lanes 1-3) and FT169A (ATM+) (lanes 4–6)
cells were treated with the protein synthesis inhibitor CHX (10 mg/ml) in the presence (lanes 3 and 6) or absence (lanes 2 and 5) of the proteasome
inhibitor MG132 (10 mM) for 6 hours. Cell lysates were analyzed by immunoblotting using an anti-STAT3 antibody as described above. Intensity of the
STAT3 band was measured using Kodak Image station 2000R (BioRad). Results are shown in a bar graph (right panel). The lower portion of the same
membrane filter was immunostained with the anti-tubulin (lower panel) antibody. All of the experiments were repeated at least three times and the
representative experiments are shown.
doi:10.1371/journal.pone.0016422.g002
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modification with Lys63-linked ubiquitin chains has been
implicated in the non-proteolytic regulation of signaling pathways
[45]. To test if the proteasome-mediated degradation of cellular
proteins is impaired in A-T cells, we examined the steady state
levels of HA-tagged Lys48- and Lys63-linked polyubiquitylated
proteins in FT169A (A-T) and FT169A (ATM+) cells in the
presence of CHX. For this purpose, the HA-Lys48-only and HA-
Lys63-only constructs were transfected into FT169A (A-T) and
FT169A (ATM+) cells. The amount of polyubiquitylated proteins
and the rate of turnover of polyubiquitylated proteins (see the
HMW protein species marked by *) were determined under the
same conditions as in Fig. 1B using the anti-HA antibody in
immunoblotting. As shown in Fig. 1C, the level of HA-Lys48-
linked polyubiquitylated proteins remained relatively unchanged
in A-T cells up to three hours in the presence of CHX (Fig. 1C, left
panel, compare lanes 1 and 2), suggesting minimal turnover of
Lys48-linked polyubiquitylated proteins in A-T cells. On the other
hand, the cellular pool of Lys48-linked polyubiquitylated proteins
was reduced by more than 70% within 3 hours in FT169A
(ATM+) cells under the same conditions (Fig. 1C, left panel,
compare lanes 3 and 4). By contrast, the levels of non-proteolytic
HA-Lys63-linked polyubiquitylated proteins remained unchanged
in both FT169A (A-T) and FT169A (ATM+) cells treated with
CHX for 3 hours (Fig. 1C, right panel, compare lanes 1–4). These
results suggest that targeted proteasome-mediated degradation of
polyubiquitylated proteins is impaired in A-T cells.
To further determine whether proteasome-mediated degrada-
tion of cellular proteins are regulated by ATM, the steady state
levels of two fluorescent reporter proteasome substrates (the N-end
rule substrate, ubiquitin-arginine-YFP (Ub-R-YFP), and the
ubiquitin fusion degradation substrate, Ub
G76V-YFP (gift from
Dr. Nico Dantuma, Karolinska Institutet, Stockholm, Sweden
[46]), were measured in FT169A (A-T) and FT169A (ATM+) cells
in the presence of CHX. Cells expressing these reporter substrates
are known to respond to functional impairment of the ubiquitin/
proteasome pathway by accumulation of the readily detectable
fluorescent reporter substrate [46]. Since these fluorescent
substrates are short lived and are degraded rapidly by the
proteasome in vivo, we pretreated cells expressing reporter YFP-
substrates with the reversible proteasome inhibitor MG132 to
enhance their accumulation. After 24 hours, cells were washed to
remove MG132-mediated block in proteasome inhibition. The
fate of these accumulated YFP-substrates was then monitored in
the presence of CHX and in the absence of MG132, and Western
blotting using anti-GFP antibodies (YFP differs from GFP due to a
mutation at T203Y. Antibodies raised against full-length GFP can
therefore detect YFP protein). As shown in Fig. 2A and B (lanes 2
and 3), little turnover of both Ub
G76V-YFP and Ub-R-YFP was
observed in FT169A (A-T) cells in the presence of CHX for up to
three hours. By contrast, both of these YFP-substrates were rapidly
degraded within 3 hours of CHX treatment in FT169A (ATM+)
cells (Fig. 2A and B, lanes 5 and 6). Turnover of non-specific band
remained unaltered under the same conditions in both of the cases
and serves as an internal control. The bar graph in the
supplementary Fig. S2 A shows average (+/- SEM) rate of
degradation of the Ub-R-YFP and Ub-G76V-YFP proteins in
FT169A (A-T) and (ATM+) cells from three independent
experiments. These results suggest that targeted proteasome-
mediated degradation of the proteasome substrates, in this case the
artificial proteasome substrates, is impaired in A-T cells.
Both p53 and STAT3 are known targets of the ubiquitin/26S
proteasome pathway [47,48]. To determine whether steady state
level of these proteins is regulated by ATM, turnover of both p53
and STAT3 were measured. As shown in Fig. 2C (upper panel,
lanes 1 and 2), little turnover of p53 was observed in FT169A (A-
T) cells in the presence of CHX for up to six hours. By contrast,
p53 protein was rapidly degraded within 6 hours of CHX
treatment in FT169A (ATM+) cells (Fig. 2C, lanes 4 and 5, and
bar graph for p53 band quantization). The turnover of p53 in the
presence of CHX was blocked by the proteasome inhibitor
MG132 (10 mM), suggesting that p53 turnover was mediated by
the 26S proteasome (Fig. 2C, compare lanes 5 and 6) in ATM+
cells. Similar results were obtained with STAT3 (see Fig. 2D and
bar graph for STAT3 quantization). The bar graph in the
supplementary Fig. S2B shows average (+/- SEM) rate of
degradation of p53 and STAT3 proteins in FT169A (A-T) and
(ATM+) cells from three independent experiments. Furthermore,
we have previously demonstrated that CPT-induced topoisomer-
ase I degradation via ubiquitin-26S proteasome is blocked in
FT169A (A-T) cells but not in FT169A (ATM+) cells [34].
Together, these results suggest that ubiquitin/26S proteasome
pathway is impaired in A-T cells. This is the first study indicating
that ubiquitin/26S proteasome pathway is impaired in A-T cells.
ATM negatively regulates the ISG15 pathway
Previous studies have shown that ISG15 is increased in A-T
lymphoblasts [35] as well as in HeLa cells transfected with ATM
siRNA [49]. Overexpression of ISG15 in tumor cells has been
linked to reduced protein polyubiquitylation and turnover [33].
To determine whether overexpression of the ISG15 pathway is
responsible for reduced protein polyubiquitylation in FT169A (A-
T) cells (Figs. 1 and 2), we measured the levels of ISG15 and its
conjugates in ATM null FT169A (A-T) and ATM-reconstituted
FT169A (ATM+) cells using anti-ISG15 antibodies by Western
analysis. As shown in the top panel of Fig. 3, no detectable ATM
protein is present in FT169A (A-T) fibroblast cells. By contrast,
ATM protein is readily detected in their corresponding wild type
cells (i.e. FT169A (ATM+) cells). The levels of both free ISG15
and ISG15 conjugates were significantly higher in FT169A (A-T)
cells than in their corresponding wild type FT169A (ATM+) cells
(Fig. 3, middle panel). The bar graph in the supplementary Fig. S3
shows average (+/- SEM) band intensities of free ISG15 proteins
in FT169A (A-T) and (ATM+) cells from three independent
experiments. Our results using A-T fibroblast cells are thus
consistent with the previous studies that, ISG15 is overexpressed in
A-T lymphoblast cells [35]. These results, together with results
shown in Fig. 1 and 2, suggest that like in tumor cells,
overexpression of the ISG15 pathway result in reduced protein
polyubiquitylation and turnover of cellular proteins in A-T cells.
siRNA-mediated knockdown of ISG15 and UbcH8
increases protein polyubiquitylation and degradation in
A-T cells
To further determine whether overexpression of ISG15 and its
conjugates in A-T cells are responsible for reduced protein
polyubiquitylation and turnover, ISG15 and UbcH8 (the cognate
E2 for ISG15 conjugation) siRNAs were employed to knockdown
the expression of ISG15 and ISG15 conjugates, respectively, in
FT169A (A-T) cells. Seventy-two hours after siRNA transfections,
cells were further transfected with HA-ubiquitin cDNA for
24 hours. ISG15 siRNA significantly reduced ISG15 expression
(70% decrease in the ISG15 band intensity) as revealed by
immunoblotting using anti-ISG15 antibody (Fig. 4A, middle
panel, compare lanes 1 and 2). UbcH8 siRNA, on the other
hand, significantly reduced the amount of ISG15-protein conju-
gates without affecting the expression level of free ISG15, as
Protein Turnover in Ataxia Telangiectasia
PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e16422revealed by immunoblotting using anti-ISG15 antibody (Fig. 4A,
second panel, compare lanes 2 and 3). Western blotting analysis of
FT169A (A-T) cells transfected with UbcH8 siRNA showed that
the expression level of UbcH8 was reduced by 70% (as judged by
the decrease in the UbcH8 band intensity) as compared to
FT169A (A-T) cells transfected with control siRNA (Fig. 4A, third
panel). By contrast, under the same conditions, the amount of HA-
ubiquitylated HMW proteins (reflecting polyubiquitylated pro-
teins), revealed by immunoblotting with anti-HA antibodies, was
greatly increased in cells treated with either ISG15 or UbcH8
siRNA than in cells treated with control siRNA (Fig. 4A, first
panel, compare lane 1 with lanes 4 and 7). The turnover of
polyubiquitylated proteins was then measured in the presence of
CHX (see Fig. 4A). As shown in the left panel of Figure 4A, the
turnover of HA-ubiquitin-conjugated proteins was negligible in
FT169A (A-T) cells (overexpressing ISG15) treated with CHX
(10 mg/ml) for 6 hours (compare lanes 1 and 3). By contrast, about
two thirds of HA-ubiquitin-conjugated proteins were degraded in
FT169A (A-T) cells transfected with either ISG15-specific (Fig. 4A,
first panel, compare lanes 4 and 6) or UbcH8-specific siRNA
(Fig. 4A, first panel, compare lanes 7 and 9) within 6 hours under
the same conditions. The same membrane filter as shown in
Fig. 4A was stripped and re-probed with anti-tubulin to assure
equal protein loading (Fig. 4A, lower panel). We also show that the
turnover of p53 and STAT3, which is reduced in FT169A (A-T)
cells transfected with control siRNA, is restored in FT169A (A-T)
cells transfected with ISG15 siRNA (Fig. 4B first and second panel,
and bar graph for quantitation). These results suggest, in part, that
protein ISGylation results in reduced protein polyubiquitylation
and turnover of cellular proteins in A-T cells. However, we cannot
rule out the possibility that the free ISG15 pool also plays an
independent role in regulating protein polyubiquitylation and
turnover in A-T cells.
Expression of ISG15 and its conjugates is elevated in cells
deficient in ATM
We also measured the levels of ISG15 and its conjugates in
several other lymphoblast and fibroblast cell lines derived from A-
T patients (A-T) and normal individuals (N). As shown in Fig. 5A,
the levels of ISG15 and its conjugates as measured by
immunoblotting using anti-ISG15 antibodies were higher in A-T
lymphoblast (left panel, lanes 2, 3 and 5) and fibroblast (right
panel, lane 2) cells. On the other hand, very little ISG15
expression (free and conjugated form) was seen in both
lymphoblast and fibroblast cells derived from normal individual
(left panel, lanes 1 and 4, and right panel, lane 1). These results,
together with the results shown in Fig. 3, strongly suggest that
ATM negatively regulates the expression of ISG15 and its
conjugates.
Expression of ISG15 and its conjugates is elevated in
brains of ATM knockout mice and A-T human patients
Our results shown in Figs 1, 2, 3, 4 suggest the possibility that
the ISG15-mediated impairment of protein degradation in A-T
neurons could be the basis of the progressive neurodegeneration in
A-T patients. To test whether ISG15 expression is also elevated in
vivo, we first assessed the expression of ISG15 and its conjugates in
various regions of brain tissues obtained from wild type and ATM
knockout mice. The levels of free ISG15 (see inserts showing lower
exposure) and its conjugates were increased in the cortex (Fig. 6,
first panel) and cerebellum (Fig. 6, second panel) parts of the brains
isolated from ATM knockout as compared to wild-type mice. In
addition, ATM knockout astrocytes exhibited striking increase in
ISG15 and its conjugates than astrocytes derived from wild-type
mice (Fig. 6, third panel).
To further examine if ISG15 expression is elevated in vivo,w e
assessed mid-brain regions (specifically containing substantia nigra)
obtained postmortem from four different A-T human patients
(with confirmed A-T disease (UMB#s 1722, 1459, 4663, and
4874)) and two control individuals (without any disease (UMB#s
1455 and 4916)) for ISG15 expression by Western blotting using
anti-ISG15 antibodies. As shown in Fig. 7 A, ISG15 and its
conjugates were highly elevated in two A-T patients (lanes 3 and
4), and moderately elevated in two other A-T patients (lanes 5 and
6) tested. On the other hand, ISG15 expression was modest in
brain tissue obtained from normal individuals (lane 1 and 2).
Figure 3. ATM negatively regulates the ISG15 pathway. Extracts
of FT169A (A-T) and FT169A (ATM+) cells were analyzed by 5% (top
panel) or 15% (middle panel) SDS-PAGE, followed by immunoblotting
using either anti-ATM (top panel) or anti-ISG15 antibody (middle panel).
The same membrane shown in the second panel was stripped and re-
probed with anti-tubulin antibody to assure equal protein loading.
Average band intensity of the free ISG15 protein (error bar represents
SEM) from three independent experiments was quantified using Kodak
Image Station 2000R and the results are shown in the bar graph.
doi:10.1371/journal.pone.0016422.g003
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mid-brain tissue sections (containing specifically substantia nigra)
obtained from a normal individual (UMB#1455) and A-T patients
(UMB# 1722, #4663, and #4874) shown in Fig. 7A, using
ISG15 (green) and Lys63-linkage-specific polyubiquitin (red)
antibodies (Fig. 7B). We used Lys63-linkage-specific antibodies
instead of ubiquitin in this experiment for the following two
reasons: i) ubiquitin antibody cross-reacts with free ISG15 [8]; and
ii) presence of the Lys63-linked polyubiquitylated proteins in the
inclusion bodies/aggregates has been documented in various
neurological disorders (Paine et al., 2008). As shown in Fig. 7B, the
dramatic increase in both ubiquitin/ISG15 double-positive
inclusions (see arrows in merged images) was found in the mid-
brain sections obtained from all three A-T patients tested. In
contrast, no such inclusions were found in brain sections of the
normal individual. We also performed an immunofluorescence
study on the mid-brain section obtained from another normal
subject (UMB# 4669); consistent with the results shown in Fig. 7B
(UMB# 1455), no ISG15 containing inclusion bodies were found
in the brain sections obtained from this normal individual using
ISG15-specific antibodies (results not shown). The presence of
ISG15/Lys63-linkage specific polyubiquitin containing inclusion
bodies in the A-T patient’s brain sections further suggests the
involvement of a defective ubiquitin-proteasome system in A-T
neurodegeneration.
Discussion
Ataxia-telangiectasia is a childhood disease with diverse clinical
manifestations that results from inactivation of the ATM kinase
[1,3]. ATM is known to play a key regulatory role in DNA repair
by transducing the DNA damage signals to cell cycle checkpoints
Figure 4. siRNA-mediated knockdown of ISG15 and UbcH8 increases protein polyubiquitylation and degradation in A-T cells. A.
FT169A (A-T) cells were treated with either control (lanes 1–3), ISG15 (lanes 4–6) or UbcH8 (lanes 7–9) siRNAs for 72 hours followed by transfection
with an HA-ubiquitin expression vector for 24 hours. Cells were treated with protein synthesis inhibitor CHX (10 mg/ml) for various times (lanes 2, 3, 5,
6, 8 and 9). Cells were then lysed with 2x SDS gel sample buffer. Cell lysates were then analyzed by immunoblotting using anti-HA antibody (first
upper panel). The same membrane shown in the first upper panel was stripped and re-probed with anti-tubulin antibody to assure equal protein
loading (first lower panel). The same samples shown in lanes 1, 4, and 7 were reloaded on a separate gel (15%), followed by immmunoblotting using
an anti-ISG15 antibody (middle panel). The same samples shown in lanes 1 and 7 along with purified UbcH8 enzyme were reloaded on a separate gel
(15%), followed by immmunoblotting using the anti-UbcH8 antibody (right panel). B. FT169A (A-T) cells were transfected with ISG15 siRNA for
72 hours. Cells were then treated with the protein synthesis inhibitor CHX (10 mg/ml) for 3 and 6 hours. Cell lysates were then analyzed by
immunoblotting using anti-p53 (top panel), anti-STAT3 (middle panel) or anti-tubulin (lower panel) antibodies. The p53 and STAT3 bands shown in
the first and second panels were quantified using the Kodak Image Station 2000R (see respective bar graphs). All the experiments were repeated at
least three times and the representative experiments are shown.
doi:10.1371/journal.pone.0016422.g004
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ATM in DNA repair is solely responsible for A-T pathogenesis. In
the current study, we have demonstrated that targeted protea-
some-mediated degradation is impaired in A-T cells. In addition,
reduced protein turnover in A-T cells is associated with elevated
expression of ISG15, an ubiquitin-like protein shown to antago-
nize the ubiquitin pathway [33]. Furthermore, ATM acts as a
suppresser of the ISG15 pathway. Our results therefore assign a
novel functional role for ATM in protein turnover through
suppression of constitutively activated ISG15 pathway in normal
Figure 5. Elevated expression of ISG15 and its conjugates in A-T cells. Normal (N) and Ataxia Telangiectasia (A-T) lymphoblast (left panel)
and fibroblast (right panel) cells were analyzed by 15% SDS-PAGE, followed by immunoblotting using anti-ISG15 antibody (upper panels). The same
membrane shown in the upper panels was stripped and re-probed using anti-b-actin antibody (lower panels). The experiment was repeated at least
three times and the representative experiment is shown.
doi:10.1371/journal.pone.0016422.g005
Figure 6. ISG15 and its conjugates are elevated in brain tissues obtained from ATM knockout mice. Lysates from cortex (left panel) and
cerebellum (middle panel) tissues, as well as primary cortical astrocytes (right panel), were immunoblotted using anti-ISG15 antibodies as described
in Material and Methods. All membrane filters were immunostained with anti-tubulin antibody (lower panels). The brain tissue lysates of two animals
were pooled and loaded on SDS-PAGE. The experiment was repeated two times with reproducible results.
doi:10.1371/journal.pone.0016422.g006
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elevated which, in turn, inhibits ubiquitin-mediated protein
turnover in A-T cells.
Defects in the ubiquitin pathway resulting in the accumulation
of non-degraded proteins in neurons have been speculated to
contribute to the neurodegenerative pathology in other neurolog-
ical diseases/proteinopathies [36–41,50,51]. A-T patients also
exhibit progressive neurodegeneration [42]. However, the cause of
neurodegeneration in A-T remains unclear. It seems reasonable to
speculate that accumulation of non-degraded proteins, as would be
predicted from our results, may contribute to progressive
neurodegeneration in A-T patients. Indeed, a couple of reports
in the literature support such a possibility. For example,
immunopositive bodies for alpha-synuclein (due to accumulation
of non-degraded alpha-synuclein) were observed in the substantia
nigra of ATM knockout mice [42]. In addition, Lewy bodies
Figure 7. Elevated expression of ISG15 and its conjugates in mid-brain tissues obtained from human A-T patients. A. Frozen mid-brain
postmortem tissues from two normal individual (UMB# 1455 and 4916) and four A-T patients (UMB #s 1722, 1459, 4663 and 4874) were weighed
and sonicated in a SDS sample buffer. Sonicated samples were immediately boiled for 10 min at 100uC and centrifuged at 13,0006g for 10 min.
Cleared supernatants were analyzed using anti-ISG15 antibodies. As a loading control, lysates were also immunoblotted aganist b-actin. B. The
deparaffinized human brain tissue sections from the normal subject (UMB# 1455) and A-T patients (UMB# 1722, 4663) described in A. were double
stained with anti-ISG15 (polyclonal) and anti-K63-linkage specific polyubiquitin (monoclonal) (1:100) antibodies. After washing with PBS, sections
were stained with Alexa Fluor 488 goat anti-rabbit IgG secondary antibody to detect ISG15 (green) and goat polyclonal secondary antibody to mouse
IgG (Cy5H) to detect Lys63-linked polyubiquitin conjugated proteins (red). Sections were mounted in gold antifade mounting medium and examined
using Nikon E600 epifluorescence microscope (Nikon) (206 magnification, scale bar, 100 um). One slide each of the deparaffinized human brain
tissue sections of A-T patients and normal individuals (obtained from the NICHD Brain and Tissue Bank for Developmental Disorders at the University
of Maryland) was used in the experiment. Arrows indicate ubiquitin/ISG15 double-positive inclusions in the A-T brain sections.
doi:10.1371/journal.pone.0016422.g007
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non-degraded ubiquitylated proteins) in the substantia nigra were
found in a patient with Ataxia-Telangiectasia [52]. In the current
study, we show that ISG15 is elevated in A-T astroglial cells and
brain tissue obtained from ATM knockout mice and patients
(Figure 6 and 7). In addition, we also show the presence of
ubiquitin/ISG15 double-positive inclusions in the brain sections
obtained from A-T patients (Fig. 7). Whether or not the elevated
expression of ISG15 impairs protein turnover and, consequently,
leads to the accumulation of ubiquitin/ISG15 inclusions in A-T
patients is unclear.
Defective DNA repair due to the mutations in ATM protein is
also implicated in A-T neurodegeneration [53]. Although our
current study points toward the possibility that the defective
protein turnover may contribute to the A-T neurodegeneration, it
does not rule out the possibility that the defective DNA repair may
also contribute to A-T pathology (neurodegeneration). In fact,
several recent studies have demonstrated that DNA repair is
regulated by ubiquitylation [54]. It is possible that both the
impaired DNA repair and targeted protein degradation (as
demonstrated in the current study), both caused due to the
defective ATM, may contribute to A-T neurodegeneration.
Studies are underway to establish the significance of ISG15-
mediated impairment of protein polyubiquitylation and turnover
in A-T pathogenesis (e.g. neurodegeneration) in our laboratory
using ATM knockout mice.
At present, it is unclear how ATM regulates the expression of
ISG15. One possibility is that ATM may negatively regulate
ISG15 expression by inhibiting expression of type I IFNs.
Concurrently, we have shown that A-T lymphoblastic L3 cells
secrete high levels of type I IFNa than ATM+ L40 cells (data not
shown). Our observation is consistent with the report that IRF1
(Interferon Regulatory Factor 1) is stabilized in ATM-deficient
cells [55]. In addition, IFNb pathway is activated in A-T cells [35].
Constitutive activation of NFkB has been suggested to be involved
in IFNb expression in A-T cells [35]. In contrast, other studies
have shown that the aberrant activation of NFkB is causally
related to the transformation process associated with SV40 large T
antigen and is not due to the inactivation of ATM in A-T cells
[56]. However, our results show that ISG15 is elevated in SV40
transformed A-T GM09607 (Fig. 3), as well as in non-transformed
A-T GM01588 cells [35]. In addition, we have demonstrated that
ISG15 expression is causally related to the ATM inactivation in A-
T cells (Fig. 3). Further, our results in ATM knockout mice and A-
T human patients (Figures 6 and 7), and HeLa cells expressing
ATM siRNA (Chen et al., 2004) strongly support a model in which
ablation of ATM kinase leads to the elevated expression of ISG15.
Our studies thus have potential clinical applications for treating A-
T patients. Development of small molecule inhibitors targeting
ISG15 pathway could prevent proteinopathy associated with A-T
and, consequently, neurodegeneration.
Materials and Methods
Ethic Statement
Human brain tissues and tissue sections were obtained from the
NICHD Brain and Tissue Bank for Developmental Disorders at
the University of Maryland (supported by NICHD contract #
N01-HD-4-3368 and N01-HD-4-3383) under ethics protocols
approved by the University of Maryland Institutional Review
Board. The NICHD Brain and Tissue Bank for Developmental
Disorders at the University of Maryland obtain informed consent
from all participants or next of kin involved in donating tissue to
the Brain and Tissue bank. Depending on the case/control, the
consent may be written or verbal. Most cases are preregistered
with the Brain and Tissue Bank (BTB) and written consent is
obtained at that time. Next of kin are consented for cases that are
not preregistered and for controls. Verbal consent is obtained
when the person giving consent does not have access to a FAX
machine or the ability to send documents by the internet, or
because of time constraints. The verbal consent process is done by
telephone using a script that is approved by both the University
IRB and Maryland State Department of Mental Health and
Hygiene. The verbal consent is confirmed by a witness who speaks
with the person (next of kin) giving consent to tissue donation. The
consent procedures have been approved by both the University of
Maryland IRB and the Maryland State Department of Mental
Health and Hygiene.
Animal study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Louisiana State University Health
Sciences Center- NO Institutional Animal Care and Use
Committee under its assurance (# A3094-0) with the Office of
Laboratory Animal Welfare of the National Institutes of Health.
Cells
Normal lymphoblast L40 and A-T lymphoblast L3 (ATM-)
cells, as well as FT169A (ATM+) and FT169A (ATM-) fibroblast
cells, were obtained from Dr. Y. Shiloh at Tel Aviv University,
Ramat Aviv, Israel. FT169A (ATM-) cells were derived from
FT169A cells (ataxia telangiectasia cells) by stable transfection with
the expression vector alone [43]. FT169A (ATM+) cells were
derived from FT169A cells by stable transfection with full-length
ATM cDNA [43]. The lymphoblast and fibroblast cells (normal
and A-T) were obtained from the American Type Culture
Collection (ATCC), Manassas, VA. FT169A (ATM+) FT169A
(ATM-) cells were cultured in DMEM supplemented with
hygromycin B (50 mg/ml). L40 and L3 cells were cultured in
RPMI medium. All other normal and A-T fibroblast cells were
cultured in DMEM and lymphoblast cells were cultured in RPMI
medium according to ATCC instructions.
Human Tissues
Tissues. Frozen human mid-brain tissues containing
specifically substantia nigra were obtained postmortem from
patients with confirmed A-T disease and control individuals
(without any known disease). Tissue sections: Slides with paraffin-
embedded sections of the same midbrain tissues described above
were used in immunoflorescence study.
Immunoblotting and immunofluorescence analysis.
Analysis of ISG15 in cultured cells. Cells (5610
5) were
cultured in 35 mm tissue culture plates. Cells were then lysed using
a SDS-PAGE sample buffer. Cell lysates were analyzed by SDS-
PAGE in 15% (unless indicated otherwise) gel and immunoblotted
according to the published procedure [57]. Cell lysates were
analyzed by immunoblotting with anti-ISG15 (raised against
human ISG15) [58], anti-ubiquitin (Sigma Chemicals), anti-HA
(gift from Dr. Walworth at RWJMS/UMDNJ), anti-p53 (Santa
Cruz), anti-STAT3 (Cell Signaling), and anti-GFP (Abcam)
antibodies as indicated using the ECL Western procedure
(Pierce) and the Kodak Image Station 2000R.
Analysis of ISG15 expression in brain tissues of Atm
knockout mice. Atm knockout mice are described in [59]. Brain
tissues were obtained from 3 week-old WT or Atm knockout
littermates and stored in liquid nitrogen prior to processing. For
detecting ISG15 and its conjugates, frozen tissues were weighed,
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PLoS ONE | www.plosone.org 10 January 2011 | Volume 6 | Issue 1 | e16422cut into small pieces, and placed in test tubes containing SDS gel
sample buffer. Tissue samples were then sonicated with a Tissue-
Tearor (Biospec Products, Inc.). Sonicated samples were
immediately boiled for 10 minutes at 100uC and then
centrifuged at 13,0006g for 10 minutes. Cleared supernatants
containing SDS-solubilized protein extracts were analyzed by
SDS-PAGE in 15% gel and immunoblotted using anti-ISG15
raised against mouse ISG15 (a gift from Dr. Knobeloch, Institute
of Molecular Pharmacology, Berlin, Germany) as described above.
Analysis of ISG15 expression in primary cortical
astrocytes. Primary cortical astrocytes prepared from the
brains of postnatal day-4 wild type and Atm knockout littermates
were maintained as monolayers in DMEM/F12 (1:1 mix)
supplemented with a 15% fetal calf serum, 2 mM L-glutamine,
100 U/ml penicillin, 100 mg/ml streptomycin, and 10 ng/ml of
mouse epidermal growth factor (Sigma, St Louis) and were used at
passage 2. Cells were lysed using an SDS gel sample buffer. SDS-
PAGE analysis and immunoblotting using mouse anti-ISG15 were
carried out as described above.
Analysis of ISG15 expression in brain tissues of A-T
patients by Western blotting. Frozen tissues were stored at
280uC until use. Tissue processing and ISG15 analysis in tissue
lysates were carried out as described above.
Analysis of ISG15 expression in brain tissue sections by
immunofluorescence staining. For double immunofluo-
rescence, tissue sections were deparaffinized in xylene and
incubated with the ISG15 (polyclonal) (1:100) and polyubiquitin
(K
63-linkage-specific) (monoclonal HWA4C4 (Biomol)) primary
antibodies (1:100) and for 1 hour. After washing in PBS, sections
were stained with Alexa Fluor 488 goat anti-rabbit IgG secondary
antibody (Invitrogen) and goat polyclonal secondary antibody to
mouseIgG (Cy5H) (Abcam).Sectionsweremountedingoldantifade
mounting medium (Invitrogen) and examined using Nikon E600
epifluorescence microscope (Nikon) (206 magnification). All the
operations were performed at room temperature.
siRNA Knockdown of ISG15
A 21-nucleotide duplex siRNA targeting ISG15, and control
siRNA were purchased from Dharmacon Research, Inc. The
siRNA targeting ISG15 corresponds to region 232–250 (Acces-
sion# AY168648). The siRNA transfection protocol was followed
with slight modifications [60]. FT169A (ATM-) cells were cultured
to semi-confluency and transfected with ISG15 siRNA using
Oligofectamine (Invitrogen). Seventy-two hours after siRNA
transfection, cells were further transfected with HA-ubiquitin
expression plasmid using PolyFect (Qiagen) for another 24 hours.
siRNA knockdown of UbcH8
A 21-nucleotide duplex siRNA targeting UbcH8 siRNA was
purchased from Dharmacon Research, Inc. The siRNA targeting
UbcH8 corresponds to the region237-255 (Accession# AF031141).
The UbcH8 siRNA transfection, followed by HA-ubiquitin
transfection, into FT169A cells was carried out as described above.
Supporting Information
Figure S1 The targeted degradation of ubiquitylated
proteins is reduced in A-T cells. FT169A (A-T) and FT169A
cells were transfected with HA-ubiquitin as described in Methods.
Forty-eight hours post-transfection, cells were treated with the
protein synthesis inhibitor CHX for 6 hours and then analyzed by
immunoblotting with anti-HA antibodies. The high molecular
weight HA-polyubiquitylated proteins (in 200 kDa compressed
band (see band marked as ** in Fig. 1B)) were detected with HA
antibodies. Average rate of degradation of high molecular weight
(HMW) HA-polyubiquitylated proteins (error bar represents
S.E.M.) in FT169A (A-T) and FT169A (ATM+) cells measured
using the Kodak image station 2000R from three independent
experiments is shown in the bar graph.
(TIF)
Figure S2 The 26S proteasome-mediated turnover of
proteins is impaired in A-T cells. A. FT169A (A-T) and
FT169A (ATM+) cells transfected with fluorescent reporter
proteasome substrates (the ubiquitin fusion degradation substrate,
Ub
G76V-YFP, and the N-end rule substrate, ubiquitin-arginine-
YFP (Ub-R-YFP) for 12 hours. Proteasome inhibitor MG132
(0.5 mM) was then added to the transfection medium and cells
were allowed to grow for an additional 12 hours. After washing (to
remove MG132), cells were treated with protein synthesis inhibitor
CHX (10 mg/ml) for three hours. The fluorescent reporter levels
were detected with GFP antibodies. Average rate of degradation of
Ub-G76V-YFP and Ub-R-YFP proteins (error bar represents
S.E.M.) in FT169A (A-T) and FT169A (ATM+) cells measured
using the Kodak image station 2000R from three independent
experiments is shown in the bar graph. B. FT169A (A-T) and
FT169A (ATM+) cells were treated with the protein synthesis
inhibitor CHX (10 mg/ml) for 6 hours. Cell lysates were analyzed
by immunoblotting using an anti-p53 and/or STAT3 antibody.
Average rate of degradation of p53 and STAT3 proteins (error bar
represents S.E.M.) in FT169A (A-T) and FT169A (ATM+) cells
measured using the Kodak image station 2000R from three
independent experiments is shown in the bar graph.
(TIF)
Figure S3 siRNA-mediated knockdown of ISG15 and
UbcH8 increases degradation of polyubiquitylated pro-
teins in A-T cells. FT169A (A-T) cells were transfected with
ISG15 or UbcH8 siRNA for 72 hours. Cells were then treated
with the protein synthesis inhibitor CHX (10 mg/ml) for 3 and
6 hours. Cell lysates were then analyzed by immunoblotting using
anti-HA antibodies. Average rate of degradation of HA-poly-
ubiquitylated proteins (error bar represents S.E.M.) in ISG15 or
UbcH8 siRNA treated FT169A (A-T) cells measured using the
Kodak image station 2000R from three independent experiments
is shown in the bar graph.
(TIF)
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